10/554,271

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	707	(556/137).CCLS.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2007/03/04 17:29
L2	905	(514/492).CCLS.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2007/03/04 17:29

10/554,271

(FILE 'HOME' ENTERED AT 16:55:19 ON 04 MAR 2007)

FILE 'REGISTRY' ENTERED AT 16:55:42 ON 04 MAR 2007
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,Cl,Br,F,I

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:56:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2475 TO ITERATE

80.8% PROCESSED 2000 ITERATIONS 28 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 46516 TO 52484
PROJECTED ANSWERS: 340 TO 1046

L2 28 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:56:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 49810 TO ITERATE

100.0% PROCESSED 49810 ITERATIONS 715 ANSWERS
SEARCH TIME: 00.00.01

L3 715 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 16:56:30 ON 04 MAR 2007

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)


```
=> s l3
L4          221 L3

=> s l4 and py<2004
      23916064 PY<2004
L5          109 L4 AND PY<2004

=> s l5 and cancer
         307771 CANCER
L6             4 L5 AND CANCER

=> d 1-4 bib abs
```

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:482176 CAPLUS
DN 138:130575
TI In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
AU Aird, R. E.; Cummings, J.; Ritchie, A. A.; Muir, M.; Morris, R. E.; Chen, H.; Sadler, P. J.; Jodrell, D. I.
CS Cancer Research UK, Edinburgh Oncology Unit, Western General Hospital, Edinburgh, EH4 2XR, UK
SO British Journal of Cancer (2002), 86(10), 1652-1657
CODEN: BJCAAI; ISSN: 0007-0920
PB Nature Publishing Group
DT Journal
LA English
AB Ruthenium complexes offer the potential of reduced toxicity, a novel mechanism of action, non-cross resistance, and a different spectrum of activity compared to Pt containing compds. Thirteen novel Rum(II) organometallic arene complexes were evaluated for activity (in vitro and in vivo) in models of human ovarian cancer, and cross-resistance profiles established in cisplatin and multi-drug-resistant variants. A broad range of IC50 values was obtained (0.5 to >100 μM) in A2780 parental cells with 2 compds. (RM175 and HC29) equipotent to carboplatin (6 μM), and the most active compound (HC11) equipotent to cisplatin (0.6 μM). Stable bi-dentate chelating ligands (ethylenediamine), a more hydrophobic arene ligand (tetrahydroanthracene) and a single ligand exchange center (chloride) were associated with increased activity. None of the 6 active Ru(II) compds. were cross-resistant in the A2780cis cell

line, demonstrated to be 10-fold resistant to cisplatin/carboplatin by a mechanism involving, at least in part, silencing of MLH1 protein expression via methylation. Varying degrees of cross-resistance were observed in the P-170 glycoprotein overexpressing multi-drug-resistant cell line 2780AD that could be reversed by co-treatment with verapamil. In vivo activity was established with RM175 in the A2780 xenograft together with non-cross-resistance in the A2780cis xenograft and a lack of activity in the 2780AD xenograft. High activity coupled to non cross-resistance in cisplatin resistant models merit further development of this novel group of anticancer compds.

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:31461 CAPLUS
DN 136:85944
TI Half-sandwich ruthenium(II) compounds comprising heteroatom containing ligands for treatment of cancer
IN Morris, Robert Edward; Sadler, Peter John; Jodrell, Duncan; Chen, Haimei
PA University Court, the University of Edinburgh, UK
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002572	A1	20020110	WO 2001-GB2824	20010626 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2414446	A1	20020110	CA 2001-2414446	20010626 <--
	EP 1294732	A1	20030326	EP 2001-945472	20010626 <--
	EP 1294732	B1	20040818		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012122	A	20030513	BR 2001-12122	20010626 <--
	JP 2004502696	T	20040129	JP 2002-507824	20010626
	AT 273985	T	20040915	AT 2001-945472	20010626
	PT 1294732	T	20041231	PT 2001-945472	20010626
	ES 2227225	T3	20050401	ES 2001-1945472	20010626
	US 2004029852	A1	20040212	US 2003-312940	20030815
	US 6936634	B2	20050830		
PRAI	GB 2000-16052	A	20000630		
	WO 2001-GB2824	W	20010626		

OS MARPAT 136:85944
GI



I

AB The preparation of compds. [I; wherein R1 and R2 together with the ring to which they are bound represent a saturated or unsatd. carbocyclic or heterocyclic group; R3, R4, R5, R6, independently = H, alkyl, aryl, alkaryl, or CO2R' (R' = alkyl, aryl, or alkaryl); X = halo, H2O, sulfoxy, carboxy, etc.; A and B, independently = O-donor, N-donor, or S-donor ligands, or halo; C' = (C1-C12)alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p = 0, 1 and r = 1 when p = 0 and r = 2 when p = 1; m = 0, 1] is described. Thus, 1,4,9,10-tetrahydroanthracene is reacted with RuCl3•3H2O to give 89% [(η6-C14H12)RuCl2]2, which was complexed with ethylenediamine (en) in the presence of NH4PF6 to give 33% [(η6-C14H12)RuCl(en)]+PF6-. Compds. I are useful as antitumor agents, exhibiting IC50 values as high as 315μM against A2780 ovarian cancer cell line. Biol. data are given.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:719202 CAPLUS
DN 136:15044
TI Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
AU Morris, Robert E.; Aird, Rhona E.; Murdoch, Piedad del Socorro; Chen, Haimei; Cummings, Jeff; Hughes, Nathan D.; Parsons, Simon; Parkin, Andrew; Boyd, Gary; Jodrell, Duncan I.; Sadler, Peter J.
CS Department of Chemistry, University of Edinburgh, Edinburgh, EH9 3JJ, UK
SO Journal of Medicinal Chemistry (2001), 44(22), 3616-3621
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Inhibition of the growth of the human ovarian cancer cell line A2780 by organometallic ruthenium(II) complexes of the type [(η6-arene)Ru(X)(Y)(Z)], where arene is benzene or substituted benzene, X, Y, and Z are halide, acetonitrile, or isonicotinamide, or X,Y is ethylenediamine (en) or N-ethylethylenediamine, has been investigated. The x-ray crystal structures of the complexes [(η6-p-cymene)Ru(en)Cl]PF6 (I), [(η6-p-cymene)RuCl2(isonicotinamide)], and [(η6-biphenyl)Ru(en)Cl]PF6 are reported. They have "piano stool" geometries with η6 coordination of the arene ligand. Complexes with X,Y as a chelated en ligand and Z as a monofunctional leaving group had the highest activity. Some complexes were as active as carboplatin. Hydrolysis of the reactive Ru-Cl bond in I was detected by HPLC but was suppressed by the addition of chloride ions. I binds strongly and

selectively to G bases on DNA oligonucleotides to form monofunctional adducts. No inhibition of topoisomerase I or II by complex I was detected. These chelated Ru(II) arene complexes have potential as novel metal-based anticancer agents with a mechanism of action different from that of the Ru(III) complex currently on clin. trial.

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:319903 CAPLUS
DN 134:326632
TI Half-sandwich ruthenium(II) compounds comprising nitrogen containing ligands for treatment of cancer
IN Morris, Robert Edward; Sadler, Peter John; Chen, Haimei; Jodrell, Duncan
PA The University Court, the University of Edinburgh, UK
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030790	A1	20010503	WO 2000-GB4144	20001026 <--
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1224192	A1	20020724	EP 2000-971599	20001026 <--
	EP 1224192	B1	20050831		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	JP 2003512471	T	20030402	JP 2001-533142	20001026 <--
	AT 303393	T	20050915	AT 2000-971599	20001026
	ES 2248136	T3	20060316	ES 2000-971599	20001026
	US 2003023088	A1	20030130	US 2002-134404	20020426 <--
	US 6750251	B2	20040615		
	US 2004220166	A1	20041104	US 2004-848416	20040518
	US 6979681	B2	20051227		
	US 2005239765	A1	20051027	US 2005-165372	20050623
PRAI	GB 1999-25274	A	19991027		
	GB 2000-16054	A	20000630		
	WO 2000-GB4144	W	20001026		
	US 2002-134404	A1	20020426		
	US 2004-848416	A1	20040518		

OS MARPAT 134:326632
GI



I

AB Title compds. I (R1, R2, R3, R4, R5, R6 = H, alkyl, -CO2R', aryl, alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R' = alkyl, aryl, alkaryl; X = halo, H2O, (R')(R'')SO, R'CO2-, (R')(R'')C:O, R'' = alkyl, aryl, alkaryl; Y = counterion; m = 0-1; q = 1-3; C' = C1-12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p = 0-1 and r = 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NR7 and B is NR9R10, wherein R7, R9 and R10 are as previously defined, and A and B are linked by an alkylene chain, optionally substituted) were prepared which may be used in the treatment and/or prevention of cancer.
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l4 and py<=2003
      23916064 PY<=2003
L7          109 L4 AND PY<=2003

=> s l7 and cancer
         307771 CANCER
L8            4 L7 AND CANCER

=> s l8 not l6
L9            0 L8 NOT L6
```